Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04409665
Other study ID # LISA KGS TRIAL 2020
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 1, 2020
Est. completion date April 30, 2022

Study information

Verified date January 2022
Source Medical University of Warsaw
Contact Tomasz Piotr Pomianek, MD
Phone 502536300
Email tomek.pomianek@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and impact of intravenous ketamine or sublingual 30% glucose as sedation drugs used in preterm premature babies during the LISA procedure. The second goal is to compare the frequency of complications during LISA with both premedication regimens.


Description:

All infants fulfilling the inclusion criteria during the 12 months recruitment window will potentially be enrolled in this randomized controlled trial of LISA premedication. Written informed consent will be acquired from parents or legal guardians. After the consent, infants needing the LISA will receive premedication as follows: caffeine citrate according to the clinical routine at study site, and randomly, either ketamine or sublingual glucose 30%. This study is a pilot study and 60 patients that will be randomized 1:1. Ketamine will be given in slow intravenous injection over 60 seconds. Glucose 30% will be given sublingually in the volume of 1 mL. After two minutes (from the end of administration of the study drug or reference drug), laryngoscopy will be started. To assess the effectiveness of both types of sedation, patients will be assessed using two pain assessment scales - the COMFORT scale and the FANS scale. 10 minutes before the procedure, the first assessment in the COMFORT and FANS scales will take place. The next assessment on both scales will take place during the procedure.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date April 30, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers No
Gender All
Age group N/A to 4 Months
Eligibility Inclusion Criteria: - Infant with established Respiratory Distress Syndrome (RDS) or at risk for RDS - Gestational age 28 0/7 - 32 6/7 weeks - Non-invasive respiratory support with nasal CPAP (incl. BiPAP) or NIPPV - Need for administration of exogenous surfactant Exclusion Criteria: - Need for intubation and mechanical ventilation at the Delivery Room - Infant with clinically significant maxillo-facial, tracheal or pulmonary malformations

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine
Patient will be sedated using Ketamine 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales
Glucose
Patient will be sedated using Glucose 2 minutes before the LISA procedure. 10 minutes prior the procedure and during the procedure the patient's pain and/or discomfort will be evaluated using COMFORT and FANS scales

Locations

Country Name City State
Poland Uniwersyteckie Centrum Zdrowia Kobiety Noworodka Warsaw Mazowieckie

Sponsors (1)

Lead Sponsor Collaborator
Medical University of Warsaw

Country where clinical trial is conducted

Poland, 

References & Publications (9)

Allegaert K, van den Anker JN. Neonatal pain management: still in search for the Holy Grail. Int J Clin Pharmacol Ther. 2016 Jul;54(7):514-23. doi: 10.5414/CP202561. Review. — View Citation

Barrington K. Premedication for endotracheal intubation in the newborn infant. Paediatr Child Health. 2011 Mar;16(3):159-71. English, French. — View Citation

Bourgoin L, Caeymaex L, Decobert F, Jung C, Danan C, Durrmeyer X. Administering atropine and ketamine before less invasive surfactant administration resulted in low pain scores in a prospective study of premature neonates. Acta Paediatr. 2018 Jul;107(7):1184-1190. doi: 10.1111/apa.14317. Epub 2018 Apr 16. — View Citation

Dekker J, Lopriore E, Rijken M, Rijntjes-Jacobs E, Smits-Wintjens V, Te Pas A. Sedation during Minimal Invasive Surfactant Therapy in Preterm Infants. Neonatology. 2016;109(4):308-13. doi: 10.1159/000443823. Epub 2016 Feb 24. — View Citation

Fernandez C, Boix H, Camba F, Comuñas JJ, Castillo F. Less Invasive Surfactant Administration in Spain: A Survey Regarding Its Practice, the Target Population, and Premedication Use. Am J Perinatol. 2020 Feb;37(3):277-280. doi: 10.1055/s-0039-1678534. Epub 2019 Feb 4. — View Citation

Kurepa D, Perveen S, Lipener Y, Kakkilaya V. The use of less invasive surfactant administration (LISA) in the United States with review of the literature. J Perinatol. 2019 Mar;39(3):426-432. doi: 10.1038/s41372-018-0302-9. Epub 2019 Jan 11. Review. — View Citation

McPherson C, Grunau RE. Neonatal pain control and neurologic effects of anesthetics and sedatives in preterm infants. Clin Perinatol. 2014 Mar;41(1):209-27. doi: 10.1016/j.clp.2013.10.002. Epub 2013 Dec 17. Review. — View Citation

McPherson C, Inder T. Perinatal and neonatal use of sedation and analgesia. Semin Fetal Neonatal Med. 2017 Oct;22(5):314-320. doi: 10.1016/j.siny.2017.07.007. Epub 2017 Jul 19. Review. — View Citation

Milesi C, Cambonie G, Jacquot A, Barbotte E, Mesnage R, Masson F, Pidoux O, Ferragu F, Thevenot P, Mariette JB, Picaud JC. Validation of a neonatal pain scale adapted to the new practices in caring for preterm newborns. Arch Dis Child Fetal Neonatal Ed. 2010 Jul;95(4):F263-6. doi: 10.1136/adc.2008.144758. Epub 2009 Feb 16. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of patient sedation Assessment of patient sedation change before and after LISA using COMFORT scale First assessment 10 minutes before procedure, second during the procedure
Primary Assessment of patient sedation Assessment of patient sedation change before and after LISA using FANS scale First assessment 10 minutes before procedure, second during the procedure
Primary Comparing ketamine and glucose Comparison of the effectiveness of sedation with ketamine and glucose using the FANS scale scores. The FANS scale ranges from 0 points at minimum to 10 points at maximum. The higher the score, the lower the sedation. Comparing the scores through study completion, an average of two years
Primary Comparing ketamine and glucose Comparison of the effectiveness of sedation with ketamine and glucose using the COMFORT scale scores. The Comfort scale ranges from 8 points at minimum, to 40 at maximum. The higher the score, the lower the sedation level. Comparing the scores through study completion, an average of two years
Secondary Frequency of complications Monitoring the possible side effects of used drugs During the procedure
See also
  Status Clinical Trial Phase
Completed NCT02522455 - Flow-cycled Ventilation in Preterm Infants N/A
Not yet recruiting NCT04019886 - Impact of Neurophysiological Facilitation of Respiration in Preterm Neonates N/A
Terminated NCT02999165 - Breastfeeding Infants Receiving Respiratory Support Trial
Completed NCT02112513 - The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome
Completed NCT02824497 - Early Neonatal Respiratory Distress: Changes in Level IIb Hospital Over a Period of One Year
Completed NCT04000568 - Breathing Variability and NAVA in Neonates
Completed NCT01926106 - Nasal Intermittent Positive-Pressure Ventilation for Twin Infants With Respiratory Distress Syndrome N/A
Completed NCT02041676 - Chest Physiotherapy Technique Increasing Inspiratory Flow on Weaning From Non Invasive Ventilation N/A
Completed NCT02819050 - Effective Approaches & Strategies to Ease Off Nasal CPAP In Preterm Infants N/A
Completed NCT02333669 - Association of SCNN1A Single Nucleotide Polymorphisms With Neonatal Respiratory Distress Syndrome N/A
Completed NCT03446937 - Effect of Antenatal Corticosteroids on Neonatal Morbidity. N/A
Terminated NCT03235986 - A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS) Phase 2
Recruiting NCT06367881 - Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS Phase 1